Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph early_phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
2(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (100.0%)

Trials by Status

not_yet_recruiting150%
enrolling_by_invitation150%

Recent Activity

0 active trials
Showing 2 of 2
enrolling_by_invitationearly_phase_1

INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer

NCT06747832
not_yet_recruitingearly_phase_1

Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia

NCT06702098

Clinical Trials (2)

Showing 2 of 2 trials
NCT06747832Early Phase 1

INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer

Enrolling By Invitation
NCT06702098Early Phase 1

Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2